39856-52-5

Usage

Uses

Used in Pharmaceutical Production:
N5,N5-Dimethylpyridine-2,5-diamine is used as a catalyst in the synthesis of pharmaceuticals for its ability to facilitate various chemical reactions, contributing to the production of a wide range of medicinal compounds.
Used in Pesticide Manufacturing:
In the agricultural sector, N5,N5-Dimethylpyridine-2,5-diamine serves as a catalyst in the manufacturing of pesticides, aiding in the creation of effective compounds to protect crops from pests and diseases.
Used in Dye Production:
N5,N5-Dimethylpyridine-2,5-diamine is also utilized in the production of dyes, where it acts as a catalyst to enhance the synthesis of colorants used in various industries, including textiles and printing.
Used as a Plastic Stabilizer:
N5,N5-Dimethylpyridine-2,5-diamine is used as a stabilizer for plastics to improve their durability and resistance to degradation, thus extending the lifespan of plastic products.
Used as a Fuel and Lubricant Additive:
In the energy sector, DMPDA is employed as an additive in fuel and lubricants to enhance their performance characteristics, such as reducing friction and improving combustion efficiency.
Used as a Corrosion Inhibitor:
N5,N5-Dimethylpyridine-2,5-diamine is used as a corrosion inhibitor in various industrial applications to protect metal surfaces from corrosion, thereby preserving the integrity and longevity of equipment and structures.
It is important to handle N5,N5-Dimethylpyridine-2,5-diamine with care due to its potential health hazards and environmental impact, ensuring proper safety measures are in place during its use and disposal.

InChI:InChI=1/C7H11N3/c1-10(2)6-3-4-7(8)9-5-6/h3-5H,1-2H3,(H2,8,9)

Upstream product

• 39856-50-3 5-bromo2-nitropyridine 
• 38772-04-2 dimethyl-(6-nitro-pyridin-3-yl)-amine 

Relevant academic research and scientific papers

Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors

CDK4/6 pathway is an attractive target for development of anti-cancer drugs. Herein, we reported the design and synthesis of a series of 4,5-dihydro-1H-pyrazolo [4,3-h]quinazoline derivatives as selective CDK4/6 inhibitors. Applied with the optimizing strategy to the initial scaffold, it is found that compound 13n is able to selectively inhibit CDK4 and CDK6 with IC50 values 0.01 and 0.026 μM, respectively. The compound showed good anti-proliferative activity when tested in a panel of tumor cell lines with CDK4/6 related mechanism of action, the results clearly suggest that compound 13n works much better than Ly2385219 which is a selective CDK4/6 inhibitor. This compound was also found to have favorable pharmacokinetic parameters. Taken together, compound 13n could be selected for further preclinical evaluation.

2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention is related to a compound of formula (I) wherein R1, R2, R3, R4 and X are as defined herein, or an acid-addition salt thereof, its preparation and therapeutic use in the treatment or prevention of diseases involving the Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1 and HZF3.

DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS

The present invention is related to a compound of formula (I): wherein R1, R2, R3, R4 and X are as defined herein, or an addition salt with an acid thereof, its pharmaceutical composition or use for treating or preventing diseases involving Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1 and HZF3.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS

The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.